| Identification | More | [Name]
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1) | [CAS]
138199-71-0 | [Synonyms]
LEVOFLOXACIN HCL
levofloxacin hydrate
LEVOFLOXACIN HYDROCHLORIDE
(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1)
LEVOFLOXACINH HYDROCHLORIDE
(S)-(-)-Ofloxacine
Levofloxacine
(-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hydrochloride
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1) | [EINECS(EC#)]
604-067-2 | [Molecular Formula]
C18H21ClFN3O4 | [MDL Number]
MFCD03265511 | [Molecular Weight]
397.83 | [MOL File]
138199-71-0.mol |
| Chemical Properties | Back Directory | [Appearance]
Pale Yellow Solid | [Melting point ]
214-216°C | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
Aqueous Base (Slightly), DMSO (Sparingly), Methanol (Slightly) | [form ]
neat | [color ]
Pale Yellow to Light Yellow | [Usage]
S-(-)-Form of Ofloxacin. An antibiotic used against gram-negative organisms | [CAS DataBase Reference]
138199-71-0(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
N | [Risk Statements ]
50/53 | [Safety Statements ]
S24/25:Avoid contact with skin and eyes . | [WGK Germany ]
3 | [HS Code ]
2934990002 |
| Hazard Information | Back Directory | [Chemical Properties]
Pale Yellow Solid | [Uses]
antibacterial | [Uses]
Levofloxacin heMihydrate is an antibiotic used against gram-negative organisms.
| [Brand name]
Iquix (Sanofi Winthrop); Levaquin
(Ortho-McNeil); Quixin (Sanofi Winthrop). | [in vivo]
Levofloxacin (10.7 mg/kg; i.p., once daily for 10 days or 3 weeks) time-dependently induces toxic effects on liver and heart in albino mice[4]. | Animal Model: | Matured male Albino mice[4] | | Dosage: | 10.7 mg/kg | | Administration: | Intraperitoneal injection; 10.7 mg/kg, once daily for 10 days or 3 weeks | | Result: | Induced severe congestion of blood vessels in the portal area, central veins with inflammatory cells infiltration, necrosis with pyknosis of cardiac muscle nuclei and apoptosis, degeneration and necrosis of hepatocytes.
|
| [IC 50]
TOPO IV | [storage]
-20°C, protect from light |
|
|